These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 20371362)

  • 1. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H
    Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors to treat liver cancer.
    Huynh H
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):13-26. PubMed ID: 20128706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Finn RS
    Clin Cancer Res; 2010 Jan; 16(2):390-7. PubMed ID: 20068087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L; Santoro A
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA; Galle PR
    Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX
    Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies for hepatocellular carcinoma.
    Skelton MR; O'Neil B
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):209-18. PubMed ID: 18391920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy of hepatocellular carcinoma: present and future.
    Chan SL; Yeo W
    J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
    Frau M; Biasi F; Feo F; Pascale RM
    Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L; Kubicka S
    Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY; Park JW
    Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.